Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argiris Symeonidis

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
American Journal of Hematology|February 22, 2023
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasmsPanagiotis T Diamantopoulos, Elena Solomou, Argiris Symeonidis, et al.
British Journal of Haematology|February 12, 2024
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO studyMatteo Sarocchi, Junmin Li, Xiao Li, et al.
Blood Advances|June 21, 2022
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AMLLionel Adès, Larisa Girshova, Vadim A Doronin, et al.
American Journal of Hematology|June 10, 2024
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myelomaSosana Delimpasi, Meletios A Dimopoulos, Jan Straub, et al.
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
Scientific Reports|October 26, 2022
Real world data on the prognostic significance of monocytopenia in myelodysplastic syndromePanagiotis T Diamantopoulos, Emmanouil Charakopoulos, Argiris Symeonidis, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Journal of Clinical Medicine|April 30, 2021
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" StudyEvangelos Terpos, Panagiotis Repousis, Chrysavgi Lalayanni, et al.
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
American Journal of Hematology|February 22, 2023
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasmsPanagiotis T Diamantopoulos, Elena Solomou, Argiris Symeonidis, et al.
British Journal of Haematology|February 12, 2024
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO studyMatteo Sarocchi, Junmin Li, Xiao Li, et al.
Blood Advances|June 21, 2022
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AMLLionel Adès, Larisa Girshova, Vadim A Doronin, et al.
American Journal of Hematology|June 10, 2024
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myelomaSosana Delimpasi, Meletios A Dimopoulos, Jan Straub, et al.
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
Scientific Reports|October 26, 2022
Real world data on the prognostic significance of monocytopenia in myelodysplastic syndromePanagiotis T Diamantopoulos, Emmanouil Charakopoulos, Argiris Symeonidis, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Journal of Clinical Medicine|April 30, 2021
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" StudyEvangelos Terpos, Panagiotis Repousis, Chrysavgi Lalayanni, et al.
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 14